Comparison between two medications in pain control of dental infection: a clinical research in patients

Not Applicable

• Conditions: Periapical Abscess, Dental Pulp Necrosis, Pain, Pain Measurement.; C01.539.830.025.650; C07.793.237.315; C23.888.592.612; E01.370.600.550.324

• Registration Number: RBR-59552p
• Lead Sponsor: Faculdade de Odontologia da Universidade Federal do Rio Grande do Sul

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-08-19
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients were included in this research according to the following criteria: individuals 18 to 80 years old; diagnosis of acute apical abscess with pulpar necrosis origin; reporting mod-erate to severe pain at the first appointment (equal or superior to 40mm on VAS).

Exclusion Criteria

They will be relieved to report being allergic to drugs not present, patients with a history of liver disease and infants.
Patients with chronic and / or anti-inflammatory opiates were also excluded, those who were or are users of substances such as crack, oxy, cocaine, marijuana and solvents. In addition, patients with cognitive (and therefore according to scales) as well as patients with cognitive impairment (and therefore from afar).

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
As a primary endpoint, the pain scores will be evaluated by means of visual analog scale (VAS) from patients with an acute dentoalveolar abscess.;The pain scores were evaluated by means of AVA of patients with an acute dentoalveolar abscess.In both groups, pain score reduction was observed over time. Significant differences were identified comparing the pain scores for 12, 24, 48, and 72 hours to the initial ones. Para-cetamol-codeine group revealed lower scores in 48 hours in relation to the initial and the 6 hours values, while 72 hours scores were lower than initial, 6 and 12 hours ones (P lower than 0,05).

Secondary Outcome Measures

Name	Time	Method
As a secondary outcome, the frequency of adverse reactions eventually described by patients will be considered, carried out through questioning in appointment.;There was no statistical difference on adverse effects between groups (P lower than 0,05). Eleven (57,9%) patients from paracetamol group and twelve (60%) patients from paraceparace-tamol-codeine group demonstrated at least one adverse effect (dizziness, drowsiness, nausea, headache, vomiting or others).